Oct 22, 2009 | Children's NSF Newsfeed
Monitoring adherence to beclomethasone in asthmatic children...
Allergy, Volume 64, Number 10, October 2009 , pp. 1458-1462 Year of publication 2009 Abstract This study was aimed to verify the adherence rate to beclomethasone dipropionate by four currently available methods.
Daily nebulizers advised for preschoolers with frequent wheezing
The most effective way to manage frequent wheezing in preschool children is regular treatment with nebulized glucocorticoids, according to a report in the October issue of Allergy.
Study Demonstrates That QVAR is More Cost-Effective Than Other...
Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd. , today announced results from an analysis of the cost-effectiveness of three different inhaled corticosteroids in a "real-life" asthmatic population.
To take donepezl orally disintgerating tablet :. a metronidazole flagyl order fast mexico, recent hitsory of heart attack.
DOR BioPharma, Inc. Receives FDA Orphan Drug Designation for orBec(R) ...
DOR BioPharma, Inc., , a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration has granted Orphan Drug Designation to Oral BDP ) for the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host disease in patients who have ...
Archives Pediatrics/Adolescent
Effects of 2 Inhaled Corticosteroids on Growth
Arch Pediatr Adolesc Med. 2001;155:1248-1254. Objective To compare the long-term effect of treatment with fluticasone propionate or beclomethasone dipropionate on growth in asthmatic children.
Long-term safety of Mometasone Furoate administered via a dry powder...
To assess the long-term pediatric safety of 2 doses of mometasone furoate administered via a dry powder inhaler for mild-to-moderate persistent asthma and compare them with that of beclomethasone dipropionate administered via a metered dose inhaler in the treatment of persistent asthma.
DOR BioPharma Announces Publication Of OrBec(R) Clinical Pulmonary...
The investigators, led by Dr. Jason Chien, reviewed data from two previous randomized, double-blind, placebo-controlled Phase 2 and 3 clinical trials evaluating orBec , for the treatment of acute GI GVHD.
Also on Topix